• 대한핵의학회:학술대회논문집
• /
• 2003.11a
• /
• pp.27.2-27.2
• /
• 2003

• Bulletin of the Korean Chemical Society
• /
• v.35 no.7
• /
• pp.2172-2174
• /
• 2014

• 대한두경부종양학회:학술대회논문집
• /
• 1996.11a
• /
• pp.265.2-266
• /
• 1996

• Proceedings of the Korean Nuclear Society Conference
• /
• 1999.10a
• /
• pp.337.1-337
• /
• 1999

• Proceedings of the Korean Society of Medical Physics Conference
• /
• 2003.09a
• /
• pp.53-53
• /
• 2003

For evaluating the feasibility of treating recurrent lesions in the vaginal cuff and cervix by hyperthermia, ultrasound applicators were designed, constructed, and characterized. For the treatment A half-cylindrical transducer Cd=1cm, length=lcm) and cylindrical transducer (d=2.5cm, length= 1.5cm) were used to construct ovoid type and cylindrical applicators. For the ovoid type applicator, each element was operated at 1.5MHz and characterized by measuring transducer efficiency and acoustic power distribution. Thermocouple probes were used to measure the temperature rise in phantom. The element sizes used in this study were selected to be comparable for high dose rate brachytherapy colpostat applicator. Each element was powered separately to achieve a desired temperature pattern in a target. The acoustic output power as a function of applied electric power of the element 1 and 2 was linear over this 1 to 40 W range and efficiencies were 32.2${\pm}$3.4% and 46.2${\pm}$0.8%, respectively. The temperature measurements in phantom showed that 6$^{\circ}C$ temperature rise was achieved at 2 cm from the applicator surface. As a conclusion, the ability of the ultrasound colpostat applicator to be used for hyperthermia was demonstrated by measuring acoustic output power, ultrasound field distribution, and temperature rise in phantom. Based on the characteristics of this applicator, it has the potential to be useful for inducing hyperthermnia to the vaginal cuff in clinic.

• 대한핵의학회:학술대회논문집
• /
• 1999.05a
• /
• pp.228-241
• /
• 1999

Percutaneous coronary angioplasty is well established therapeutic modality in the management of coronary artery disease. However, the high restenosis rate of 30 to 50% limits its usefulness. The principal mechanism of restenosis, intimal hyperplasia, is the proliferative response of vessel wall to injury, which consists largely of smooth muscle cells. A large body of animal investigations and a limited number of clinical studies have established the ability of ionizing radiation to reduce neointimal proliferation and restenosis rate significantly. Human studies have been reported that intravascular radiation after first restenosis inhibits a second restenosis. Encouraged by these reports, we are also conducting a double blind, placebo-controlled, randomized trial to evaluate this new therapeutic modality in patients with coronary artery stenosis. The objective of our trial is to determine the safety and efficacy of catheter-based solutional beta emitting radioisotope system in preventing restenosis after angioplasty. This review describes the vascular brachytherapy systems and isotopes that have been utilized in the initial clinical trials performed in this area of post PTCA coronary restenosis. The results of many worldwide ongoing clinical trials will determine whether this new technology will change the future practice of vascular intervention.

• Radiation Oncology Journal
• /
• v.5 no.2
• /
• pp.137-140
• /
• 1987

In brachytherapy of uterine conical cancer using a high dose rate remote afterloading system, it is of prime importance to deliver a accurate dose in each fractionated treatment by minimizing the difference between the pre-treatment planned and post-treatment calculated doses. The post-treatment calculated point A dose was not much different from the pretreatment planned dose (500 cGy). The $average{\pm}standard$ deviation was $500\pm18cGy$ and 84 percent of 82 intracavitary radiotherapy was within the range of $500\pm25cGy$.

• Korean Journal of Head & Neck Oncology
• /
• v.4 no.1
• /
• pp.13-19
• /
• 1988

Brachytherapy is known to be a good modality to achieve local control as a boost treatment following limited external irradiation, which may reduce the external beam related acute radiation sickness, particularly in head and neck cancer. The authors developed iridium-192 ribbons recently to replace the radium needles. Total of 13 head and neck cancer patients had been treated with Ir-192 ribbons during last one year from October 1986 to September 1987, and the results were analysed to assess the applicability of the fabricated sources. The conclusion is as follows; 1) Iridium implant achieved 54% (7/13) of complete response and 69% (9/13) of overall response rate in head and neck cancer. 2) Iridium is superior to radium and cecium in brachytherapy because of easier to use and lesser exposure to the personnel. 3) Afterloading technique is useful to modify dose distribution, to expand treatment site and method, and to develop interstitial hyperthermia.

• The Journal of Korean Society for Radiation Therapy
• /
• v.6 no.1
• /
• pp.56-60
• /
• 1994

In the past, brachytherapy was carried out mostly with radium or radon sources. Currently. use of artificially produced radionuclially produced radionuclides such as $^{137}Cs,\;^{192}Ir,\;^{198}Au,\;and\;^{125}I$ is rapidly increasing. Although electrons are often used as an alternative to interstitial implants, brachytherapy continues to remain an important mode of therapy, either alone or combined with external beam. The National Council on Radiation Protection and Measurements(NCRP) recommends that the strength of any ${\gamma}$ emitter should be specified directly in terms of exposure rate in air at a specified distance such as 1m. The air kerma strength is defined as the product of air kerma rate in 'free space' and the square of the disrance of the calibration point from the source center along the perpendicular bisector, i. e., $S_k=K_L{\times}L^2$. Where $S_K$ is the the air kerma strength and K is the air kerma rate at a specified distance L. (usually 1m). Recommended units for all kerma strength are ${\mu}Gym^{2}h^{-1}$.

• Progress in Medical Physics
• /
• v.14 no.1
• /
• pp.15-19
• /
• 2003

High dose rate (HDR) brachytherapy for treating a cervix carcinoma has become popular, because it eliminates many of the problems associated with conventional brachytherapy. In order to improve the clinical effectiveness with HDR brachytherapy, a dose calculation algorithm, optimization procedures, and image registrations need to be verified by comparing the dose distributions from a planning computer and those from a phantom. In this study, the phantom was fabricated in order to verify the absolute doses and the relative dose distributions. The measured doses from the phantom were then compared with the treatment planning system for the dose verification. The phantom needs to be designed such that the dose distributions can be quantitatively evaluated by utilizing the dosimeters with a high spatial resolution. Therefore, the small size of the thermoluminescent dosimeter (TLD) chips with a dimension of <1/8"and film dosimetry with a spatial resolution of <1mm used to measure the radiation dosages in the phantom. The phantom called a pelvic phantom was made from water and the tissue-equivalent acrylic plates. In order to firmly hold the HDR applicators in the water phantom, the applicators were inserted into the grooves of the applicator holder. The dose distributions around the applicators, such as Point A and B, were measured by placing a series of TLD chips (TLD-to-TLD distance: 5mm) in the three TLD holders, and placing three verification films in the orthogonal planes. This study used a Nucletron Plato treatment planning system and a Microselectron Ir-192 source unit. The results showed good agreement between the treatment plan and measurement. The comparisons of the absolute dose showed agreement within $\pm$4.0 % of the dose at point A and B, and the bladder and rectum point. In addition, the relative dose distributions by film dosimetry and those calculated by the planning computer show good agreement. This pelvic phantom could be a useful to verify the dose calculation algorithm and the accuracy of the image localization algorithm in the high dose rate (HDR) planning computer. The dose verification with film dosimetry and TLD as quality assurance (QA) tools are currently being undertaken in the Catholic University, Seoul, Korea.